advertisement
Advances in Therapy 32
Showing records 1 to 25 | Display all abstracts in Advances in Therapy109687 Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations
Pearl NZ
Advances in Therapy 2023; 40: 3626-3638
109855 Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study
Inatani M
Advances in Therapy 2023; 40: 4074-4092
109609 Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine
Tanihara H
Advances in Therapy 2023; 40: 3559-3573
109669 Analyses of Dupilumab-Related Ocular Adverse Drug Reactions Using the WHO's VigiBase
Hirai E
Advances in Therapy 2023; 40: 3830-3856
109609 Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine
Yamamoto T
Advances in Therapy 2023; 40: 3559-3573
109855 Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study
Orii Y
Advances in Therapy 2023; 40: 4074-4092
109687 Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations
Babin CP
Advances in Therapy 2023; 40: 3626-3638
109669 Analyses of Dupilumab-Related Ocular Adverse Drug Reactions Using the WHO's VigiBase
Haruki T
Advances in Therapy 2023; 40: 3830-3856
109687 Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations
Catalano NT
Advances in Therapy 2023; 40: 3626-3638
109669 Analyses of Dupilumab-Related Ocular Adverse Drug Reactions Using the WHO's VigiBase
Baba T
Advances in Therapy 2023; 40: 3830-3856
109855 Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study
Iwasaki K
Advances in Therapy 2023; 40: 4074-4092
109609 Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine
Aihara M
Advances in Therapy 2023; 40: 3559-3573
109669 Analyses of Dupilumab-Related Ocular Adverse Drug Reactions Using the WHO's VigiBase
Miyazaki D
Advances in Therapy 2023; 40: 3830-3856
109855 Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study
Arimura S
Advances in Therapy 2023; 40: 4074-4092
109669 Analyses of Dupilumab-Related Ocular Adverse Drug Reactions Using the WHO's VigiBase
Miyazaki D
Advances in Therapy 2023; 40: 3830-3856
109687 Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations
Blake JC
Advances in Therapy 2023; 40: 3626-3638
109609 Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine
Koizumi N
Advances in Therapy 2023; 40: 3559-3573
109687 Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations
Ahmadzadeh S
Advances in Therapy 2023; 40: 3626-3638
109609 Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine
Minami H
Advances in Therapy 2023; 40: 3559-3573
109855 Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study
Sunagawa H
Advances in Therapy 2023; 40: 4074-4092
109609 Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine
Kojima S
Advances in Therapy 2023; 40: 3559-3573
109687 Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations
Shekoohi S
Advances in Therapy 2023; 40: 3626-3638
109855 Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study
Shiokawa M
Advances in Therapy 2023; 40: 4074-4092
109609 Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine
Isobe T
Advances in Therapy 2023; 40: 3559-3573
109687 Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations
Kaye AD
Advances in Therapy 2023; 40: 3626-3638
